tiprankstipranks
Trending News
More News >

Organovo to present data of FXR314 in Phase 2 MASH study

Organovo (ONVO) announces that its lead clinical stage drug, FXR314 will be featured in an oral presentation at The Liver Meeting, sponsored by the American Association for the Study of Liver Diseases, AASLD. The presentation, by Dr. Eric Lawitz of the Texas Liver Institute, will describe the findings from the FXR314 Phase 2 MASH study. The meeting will be held November 15-19, 2024 in San Diego, California.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue